Abstract
Aims
To determine the safety and efficacy of insulin degludec versus glargine in patients with type 1 (T1D) and type 2 (T2D) diabetes mellitus.
Methods
Databases were searched until July 5, 2017. We included randomized controlled trials comparing degludec with glargine in diabetic patients, each with a minimum of 16 weeks of follow-up.
Results
Eighteen trials with 16,791 patients were included. Degludec was associated with a statistically significant reduction in risk for all confirmed hypoglycemia at the maintenance treatment period [estimated rate ratio (ERR) 0.81; 95% confidence interval (CI) 0.72‒0.92; P = 0.001], nocturnal confirmed hypoglycemia at the entire (ERR 0.71; 95% CI 0.63‒0.80; P < 0.001) and maintenance treatment period (ERR 0.65; 95% CI 0.59‒0.71; P < 0.001), all irrespective of the pooled diabetic populations and follow-up durations. The differences in the rate of hypoglycemia were more pronounced in nocturnal period and maintenance period and in T2D than T1D patients. Degludec reduced the incidence of severe hypoglycemia in T2D [ERR 0.65; (0.52; 0.89); P = 0.005] but not T1D patients. HbA1c concentration was slightly higher in degludec over glargine but was not clinically relevant [estimated treatment difference (ETD) 0.03; 95% CI − 0.00 to 0.06%; P = 0.06]. Fasting plasma glucose level was lower in degludec-treated patients (ETD − 0.28 mmol/L; 95% CI − 0.44 to − 0.11 mmol/L; P = 0.001). Several subgroup analyses showed largely consistent findings. The rates of adverse events including total mortality and cardiovascular events were not significantly different between two treatment strategies.
Conclusions
Insulin degludec appears to have better safety in reducing hypoglycemic events with similar efficacy compared with insulin glargine.
Similar content being viewed by others
References
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577–1589
Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ et al (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643–2653
Curtis B, Lage MJ (2014) Glycemic control among patients with type 2 diabetes who initiate basal insulin: a retrospective cohort study. J Med Econ 17:21–31
Heise T, Nosek L, Ronn BB, Endahl L, Heinemann L, Kapitza C et al (2004) Lower within-subject variability of insulin detemirin comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 53:1614–1620
Ashwell SG, Bradley C, Stephens JW, Witthaus E, Home PD (2008) Treatment satisfaction and quality of life with insulin glargine plus insulin lispro compared with NPH insulin plus unmodified human insulin in individuals with type 1 diabetes. Diabet Care 31:1112–1117
Pettus J, Santos CT, Tamborlane WV, Edelman S (2016) The past, present, and future of basal insulins. Diabetes Metab Res Rev 32:478–496
Vora J, Cariou B, Evans M, Gross JL, Harris S, Landstedt-Hallin L et al (2015) Clinical use of insulin degludec. Diabet Res Clin Pract 109:19–31
Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H (2012) Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabet Obes Metab 14:859–864
Heise T, Nosek L, Bottcher SG, Hastrup H, Haahr H (2012) Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabet Obes Metab 14:944–950
Heller S, Buse J, Fisher M, Garg S, Marre M, Merker L et al (2012) Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 379:1489–1497
Garber AJ, King AB, Del PS, Sreenan S, Balci MK, Munoz-Torres M et al (2012) Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 379:1498–1507
Ratner RE, Gough SC, Mathieu C, Del PS, Bode B, Mersebach H et al (2013) Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabet Obes Metab 15:175–184
Sorli C, Warren M, Oyer D, Mersebach H, Johansen T, Gough SC (2013) Elderly patients with diabetes experience a lower rate of nocturnal hypoglycaemia with insulin degludec than with insulin glargine: a meta-analysis of phase IIIa trials. Drugs Aging 30:1009–1018
Goto A, Arah OA, Goto M, Terauchi Y, Noda M (2013) Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ 347:f4533
McCoy RG, Van Houten HK, Ziegenfuss JY, Shah ND, Wermers RA, Smith SA (2012) Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care 35:1897–1901
Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L et al (2010) Severe hypoglycemia and risks of vascular events and death. N Engl J Med 363:1410–1418
Lane W, Bailey TS, Gerety G, Gumprecht J, Philis-Tsimikas A, Hansen CT et al (2017) Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 1 diabetes: the SWITCH 1 randomized clinical trial. JAMA 318:33–44
Wysham C, Bhargava A, Chaykin L, de la Rosa R, Handelsman Y, Troelsen LN et al (2017) Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 2 diabetes: the SWITCH 2 randomized clinical trial. JAMA 318:45–56
Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR et al (2017) Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med 377:723
Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151(264–269):W64
Higgins JPT, Altman DG, Sterne JAC (2011) Assessing risk of bias in included studies. In: Higgins JPT, Green S (eds) Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. www.cochrane.org/resources/handbook. 15 Dec 2015
Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560
Zinman B, DeVries JH, Bode B, Russell-Jones D, Leiter LA, Moses A et al (2013) Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials. Lancet Diabet Endocrinol 1:123–131
Heise T, Tack CJ, Cuddihy R, Davidson J, Gouet D, Liebl A et al (2011) A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial. Diabet Care 34:669–674
Zinman B, Philis-Tsimikas A, Cariou B, Handelsman Y, Rodbard HW, Johansen T et al (2012) Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabet Care 35:2464–2471
Gough SC, Bhargava A, Jain R, Mersebach H, Rasmussen S, Bergenstal RM (2013) Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial. Diabet Care 36:2536–2542
Onishi Y, Iwamoto Y, Yoo SJ, Clauson P, Tamer SC, Park S (2013) Insulin degludec compared with insulin glargine in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, Pan-Asian, treat-to-target trial. J Diabet Investig 4:605–612
Onishi Y, Ono Y, Rabol R, Endahl L, Nakamura S (2013) Superior glycaemic control with once-daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial. Diabet Obes Metab 15:826–832
Kumar A, Franek E, Wise J, Niemeyer M, Mersebach H, Simo R (2016) Efficacy and safety of once-daily insulin degludec/insulin aspart versus insulin glargine (U100) for 52 weeks in insulin-naive patients with type 2 diabetes: a randomized controlled trial. PLoS ONE 11:e163350
Pan C, Gross JL, Yang W, Lv X, Sun L, Hansen CT et al (2016) A multinational, randomized, open-label, treat-to-target trial comparing insulin degludec and insulin glargine in insulin-naive patients with type 2 diabetes mellitus. Drugs R D 16:239–249
Kumar S, Jang HC, Demirag NG, Skjoth TV, Endahl L, Bode B (2017) Efficacy and safety of once-daily insulin degludec/insulin aspart compared with once-daily insulin glargine in participants with Type 2 diabetes: a randomized, treat-to-target study. Diabet Med 34:180–188
Meneghini L, Atkin SL, Gough SC, Raz I, Blonde L, Shestakova M et al (2013) The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. Diabet Care 36:858–864
Mathieu C, Hollander P, Miranda-Palma B, Cooper J, Franek E, Russell-Jones D et al (2013) Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab 98:1154–1162
Birkeland KI, Home PD, Wendisch U, Ratner RE, Johansen T, Endahl LA et al (2011) Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabet Care 34:661–665
Heller S, Mathieu C, Kapur R, Wolden ML, Zinman B (2016) A meta-analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia. Diabet Med 33:478–487
Russell-Jones D, Gall MA, Niemeyer M, Diamant M, Del PS (2015) Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: a meta-analysis of seven clinical trials. Nutr Metab Cardiovasc Dis 25:898–905
Monami M, Mannucci E (2013) Efficacy and safety of degludec insulin: a meta-analysis of randomised trials. Curr Med Res Opin 29:339–342
Singh SR, Ahmad F, Lal A, Yu C, Bai Z, Bennett H (2009) Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. CMAJ 180:385–397
Horvath K, Jeitler K, Berghold A, Ebrahim SH, Gratzer TW, Plank J et al (2007) Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007:D5613
Lingvay I, Perez MF, Garcia-Hernandez P, Norwood P, Lehmann L, Tarp-Johansen MJ et al (2016) Effect of insulin glargine up-titration vs insulin degludec/liraglutide on glycated hemoglobin levels in patients with uncontrolled type 2 diabetes: the DUAL V randomized clinical trial. JAMA 315:898–907
Zinman B, Marso SP, Poulter NR, Emerson SS, Pieber TR, Pratley RE et al (2018) Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2). Diabetologia 61:48–57
Pieber TR, Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS et al (2018) DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality. Diabetologia 61:58–65
Seaquist ER, Chow LS (2017) Hypoglycemia in diabetes: does insulin type matter? JAMA 318:31–32
Funding
The work was supported by the National Natural Science Foundation of China (No. 81600312). The funders had no role in the study design, data collection and analysis, writing of the report, and decision to submit the article for publication.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
None.
Human and animal rights
This article does not contain any studies with human or animal subjects performed by the any of the authors.
Informed consent
All of the eligible articles included in the meta-analysis stated that they had obtained informed consent from participants.
Additional information
Managed by Massimo Porta.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Zhang, XW., Zhang, XL., Xu, B. et al. Comparative safety and efficacy of insulin degludec with insulin glargine in type 2 and type 1 diabetes: a meta-analysis of randomized controlled trials. Acta Diabetol 55, 429–441 (2018). https://doi.org/10.1007/s00592-018-1107-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00592-018-1107-1